Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients:...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Casagrande
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors M. Casagrande1, R. Moretto2, F. Loupakis3, C. Cremolini3, G. Masi4, B. Borelli5, S. Lonardi6, A. Marsico Valentina7, L. Salvatore3, D. Rossini3, L. Ferrari1, V. Ricci8, R. Grande9, G. Tomasello10, M. Ronzoni11, G. Allegrini12, G. Tonini13, M. Mancini14, A. Zaniboni15, S. Chiara16, C. Carlomagno17, A. Falcone18
  • 1Department of Oncology, University Hospital, Udine, Italy, /
  • 2Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, /
  • 3Oncologia Medica 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, /
  • 4U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, /
  • 5Oncologia Medica 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, /
  • 6Oncologia Medica 1, Istituto Oncologico Veneto - IRCCS, Padova, Italy, /
  • 7Istituto Oncologico Veneto - IRCCS, Padova, Italy, /
  • 8Medical Oncology, Oncology Department, S. Croce & Carle Teaching Hospital Cuneo, Cuneo, Italy, /
  • 9Medical Oncology Unit, ASL Frosinone, Frosinone, Italy, /
  • 10Medical Oncology Division, Istituti Ospitalieri di Cremona, Cremona, Italy, /
  • 11Dipartimento di Oncologia, Istituto Scientifico San Raffaele, Milano, Italy, /
  • 12U.O. Oncologia Medica, Azienda USL-5 Istituto Toscano Tumori, Pontedera, Italy, /
  • 13Università Campus Bio-Medico, Rome, Italy, /
  • 14Sapienza University of Rome, Rome, Italy, /
  • 15Fondazione Poliambulanza, Brescia, Italy, /
  • 16U.O. Oncologia Medica 2 IRCCS Azienda Ospedaliera Universitaria “San Martino” - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, /
  • 17Azienda Ospedaliera Universitaria Federico II, Napoli, Italy, /
  • 18Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, /

Abstract

Elderly metastatic colorectal cancer (mCRC) patients (pts) are underrepresented in clinical trials and present heterogeneous physiological and chronological age, general conditions, and comorbidities. Pts between 71 and 75 years old, with ECOG PS 0 were eligible for GONO studies investigating the intensified triple regimen FOLFOXIRI with or without targeted agents as first-line treatment of mCRC. The aim of this analysis was to assess the safety and efficacy of FOLFOXIRI-based regimens in this subpopulation.